J Pediatr Urol by Plank, Rebeca M. et al.
Loss of Anatomical Landmarks with Eutectic Mixture of Local
Anesthetic Cream for Neonatal Male Circumcision
Rebeca M. Plank, MD,
Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, United States.
Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston,
United States. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
David W. Kubiak, Pharm D, BCPS,
Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, United States. Dana-
Farber Cancer Institute, Boston, United States
Rasak Bamidele Abdullahi, MD, MPH,
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
Nnamdi Ndubuka, MB BS, MPH,
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
Maggie M. Nkgau, RN,
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
Fredrick Dapaah-Siakwan, MB ChB,
Scottish Livingstone Hospital, Molepolole, Botswana
Kathleen M. Powis, MD, MPH, and
Departments of Internal Medicine and Pediatrics, Massachusetts General Hospital, Boston,
Unites States. Department of Immunology and Infectious Diseases, Harvard School of Public
Health, Boston, United States. Botswana Harvard AIDS Institute Partnership, Gaborone,
Botswana
Shahin Lockman, MD, MSc
Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, United States.
Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston,
Unites States. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
Abstract
© 2012 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
Contact: 15 Francis Street PBB-A-4 Boston, MA 02115, Phone: 617-525-9656, Fax: 617-732-6829, rplank@partners.org.
Conflict of interest statement
None of the authors has any financial or personal relationships with other people or organisations that could inappropriately influence
his or her work.
Ethical Approval
The study was approved by the Botswana Ministry of Health’s Health Research and Development Committee and by Partners
Institutional Review Board (Brigham and Women’s Hospital). Written informed consent was obtained from the mothers for the
procedure and for the photos.
The larger trial is registered at www.clinicaltrials.gov as NCT00971958.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
J Pediatr Urol. Author manuscript; available in PMC 2014 February 01.
Published in final edited form as:













We report two cases of newborns who developed marked local edema after application of a
eutectic mixture of local anesthetic (EMLA) topical anesthetic cream for neonatal male
circumcision (NMC). Although local edema and erythema are known potential side effects of
EMLA cream, a common anesthetic used for NMC, the loss of landmarks precluding safe NMC
has not previously been reported, and is described here. Although we cannot recommend an
alternate local anesthetic for neonates with this reaction to EMLA, based on a review of the
published data we think that serious systemic adverse events related to EMLA are extremely rare.
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Background
Local anesthesia is routinely used during NMC. Methods of pain control studied for NMC
include injected lidocaine for dorsal penile nerve block (DPNB) or ring block, topical
lidocaine, topical EMLA (2.5% lidocaine and 2.5% prilocaine) cream, acetaminophen and
sucrose/dextrose pacifiers. Many practitioners advocate a combination of interventions, such
as injectable anesthesia together with sucrose pacifiers1. While mild to moderate blanching,
erythema and edema2–4 are known potential side effects of EMLA cream, we do not know
of cases in which the topically applied anesthesia resulted in loss of landmarks necessary for
safe NMC.
Although clinical trials have concluded that DPNB is more effective for pain control than
topical anesthetic creams during NMC1, the latter have some practical advantages. Topical
anesthetic creams avoid pain of the injection, avoid potential complications from inadvertent
intravascular injection, including overdose5, and eliminate potential nosocomial infections,
such as methicillin-resistant Staphylococcus aureus, that have been reported with multiuse
vials of injectable anesthetics6. They do not require new needles and syringes and reduce the
need for sharps disposal, important in resource-limited settings7. Additionally, they can be
applied safely by non-physician providers, a vital issue for settings where physicians’ time is
limited8, 9.
Male circumcision has been demonstrated to reduce heterosexual acquisition of HIV in men
by about 60% 10–12 and to reduce significantly the acquisition of human papilloma virus and
herpes simplex virus13. The World Health Organization (WHO) recommends “that male
circumcision should be recognized as an efficacious intervention for HIV risk reduction”14.
WHO further states that, “Since neonatal circumcision is a less complicated and risky
procedure than circumcision performed in young boys, adolescents or adults … countries
should consider how to promote neonatal circumcision in a safe, culturally acceptable and
sustainable manner”14. NMC is not, however, currently a routine practice in southern Africa.
In keeping with the WHO guidelines, we are conducting a pilot study of the safety,
feasibility and uptake of NMC in Botswana and, for the reasons noted above, we selected
EMLA cream as the anesthetic of choice.
Cases Reports
Case 1
Infant 1 was born at estimated 39 weeks gestation, weighing 2.73 kg. On day 2 of life, his
family requested circumcision. Initial examination of the infant by the nurse midwife
revealed normal external male genitalia. As per protocol, approximately 1 gram of EMLA
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cream was applied to the penis and covered with an occlusive dressing. Approximately 2
hours later he was brought to the study physician for circumcision. On examination at that
time the foreskin was edematous and no corona was discernable (Figures 1a and 1b). EMLA
cream was removed and the newborn was not circumcised. He had no other local or
systemic signs of reaction to the medication. He was discharged home in good condition. He
was examined 96 hours later and found to have normal uncircumcised external male
genitalia (Figure 1c).
Case 2
Infant 2 was born at estimated 41 weeks gestation, weighing 3.32 kg. On day 2 of life, his
family requested circumcision. Initial examination of the infant by the nurse midwife
revealed normal external male genitalia. Approximately 1 gram of EMLA cream was
applied to the penis and covered with an occlusive dressing. Approximately 2 hours later he
was brought to the study physician for circumcision. On examination at that time the
foreskin was markedly edematous and no corona was discernable (Figure 2a). EMLA cream
was removed and the newborn was not circumcised. He had no other local or systemic signs
of reaction to the medication. He was examined 24 hours later and found to have normal
uncircumcised external male genitalia (Figure 2b).
The same tube of EMLA was used for the two infants and also for several other infants who
did not experience any discernable reaction. In more than 450 NMCs performed at our site
these are the only two such reactions we have seen. The typical reaction we have seen in our
practice is mild edema of the distal foreskin (Figure 3).
Discussion
Transient local reactions to EMLA cream are not uncommon2–4, 9, 15. One series reported
erythema and mild blistering of the foreskin; this is the only published report we found
(using PubMed keyword search “EMLA” and “circumcision”) in which EMLA cream
precluded NMC16. We report here for the first time loss of anatomical landmarks secondary
to marked local edema after the application of EMLA cream that precluded NMC. No other
local or systemic adverse events were noted in these cases.
Previous clinical trials with EMLA cream for NMC have used doses ranging from 0.5 grams
– 5.0 grams left under an occlusive dressing from 30 – 120 minutes or more9, 17–19.
Although longer application time (2–3 hours) results in maximal anesthetic effect20, this
must be weighed against the concern for local side effects and for systemic absorption of the
anesthetic agents which increases with size of the application area, amount of cream applied
and duration of application. The development of a local reaction to EMLA cream does not in
itself indicate an increased risk for systemic toxicity.
The most common concern for systemic toxicity is methemoglobinemia, which has been
reported after the use of some local anesthetic agents, such as injected prilocaine21.
Methemoglobinemia is the oxidation of the iron moiety within the hemoglobin molecule that
results in effective tissue hypoxia. This rare complication is of special concern in neonates,
as they have a relative deficiency of the enzyme required to reduce methemoglobin (mtHB).
Immature skin barrier and relatively high ratio of surface area to body weight are additional
risk factors placing neonates at greater risk for systemic toxicity from mtHB-inducing
agents. The manufacturer of EMLA cream, AstraZeneca, warns: “EMLA Cream should not
be used in neonates with a gestational age less than 37 weeks nor in infants under the age of
twelve months who are receiving treatment with [other] methemoglobin-inducing agents”.
Of note: neither infant in this series had received any other potentially mtHB-inducing
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agents. The manufacturer also recommends that for children 0–3 months or < 5 kg, the dose
not exceed 1 gram applied to more than 10 cm2 and application no more than 1 hour20.
Nonetheless, in published studies of EMLA cream for NMC in which serum levels of mtHB
were measured, no infant was found to have toxic levels. One study found no difference in
percentage of mtHB concentration in blood between infants who received EMLA cream (1
gram for 60–80 min) and those who received no anesthetic (mean mtHB concentration
1.3±0.6 % in EMLA cream group and 1.3±0.2 % in placebo group, P = 0.80)15. Although
another study showed no significant difference in the mean mtHB concentration among
infants who received EMLA cream (1.3%) (2 grams for at least 90 minutes) and those who
received placebo (0.6%) or injected lidocaine for DPNB (0.7%) or injected lidocaine for ring
block (0.4%), two infants in the EMLA cream group had mtHB levels of 2.4% and 4.5%,
respectively, and no treatment was required22. A third study showed that although levels of
methemoglobin increased from baseline in infants treated with EMLA cream prior to
circumcision, they did not exceed normal values23.
Though we do not have the capacity to measure serum mtHB concentration at our facilities,
the two newborns discussed here did not develop any pallor or cyanosis, findings known to
develop as a result of methemoglobinemia when serum levels of mtHB exceed about 5%.
For other clinical signs and symptoms of methemoglobinemia to become apparent, mtHB
levels usually exceed 30%24. Searching PubMed “eutectic mixture of local anesthetic” or
“EMLA” and “methemoglobinemia”, we find two case reports of infants developing
methemoglobinemia after application of EMLA cream for NMC: in one case 3.5 grams were
applied for an hour and in another case an unknown amount was applied for 3 hours. In both
cases the infants were noted to have changes in skin color that prompted testing for
methemoglobinemia. Both infants had methemoglobin levels of 16%. No treatment other
than supplemental oxygen was required and no other sequelae were noted25, 26. A published,
systematic review of EMLA cream in neonates, not limited to use for NMC, found no
clinically significant cases of methemoglobinemia, with a maximum measured value of
16%27.
The question remains as to what local anesthetic would be safe to use in neonates
experiencing local tissue edema secondary to EMLA cream. As both lidocaine and
prilocaine have been independently reported to cause tissue edema, we do not feel
comfortable recommending other preparations of prilocaine or lidocaine (either injectable or
topical) in individuals who have had this reaction to EMLA cream. The US Food and Drug
Administration recommends avoiding benzocaine in children less than 4 months of age28.
Although tetracaine is an ester-type (while lidocaine and prilocaine are both amide-type)
local anesthetic and this may suggest reduced risk of cross-reactivity29, tetracaine has not
been studied in NMC so we cannot currently recommend its use. Infants with localized
reactions to EMLA cream may have to wait until they are old enough to undergo the
procedure under general anesthesia if so desired.
It is important to emphasize that NMC is an elective procedure and should only be
undertaken when providers can ensure there are no unnecessary risks resulting from the
conditions under which it is performed. Providers must be encouraged to evaluate each
neonate carefully and be willing to abandon the procedure in circumstances such as the one
described here.
Conclusions
Although EMLA cream has a number of advantages over injectable formulations and
serious adverse reactions are extremely rare, providers should be aware that one potential
side effect is marked edema resulting in the complete loss of anatomical landmarks
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necessary for safe NMC. It is not clear whether this is related to duration of application. We
do not recommend re-challenge with EMLA cream.
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Infant 1: a) about 2 hours after application of EMLA, with localized bullous edema of distal
foreskin with obliteration of normal anatomical landmarks; b) ventral aspect of penis
showing spread of edema along median raphe. Note obliteration of the perimeter of the
coronal sulcus that would usually be apparent beneath the foreskin: c) Follow-up 96 hours
later reveals normal uncircumcised penis and discernable coronal sulcus.
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Infant 2: a) about 2 hours after application of EMLA, with localized bullous edema of distal
foreskin with obliteration of normal anatomical landmarks: b) Follow-up 24 hours later
reveals normal uncircumcised penis.
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Typical reaction to EMLA with mild edema of the distal foreskin.
Plank et al. Page 9
J Pediatr Urol. Author manuscript; available in PMC 2014 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
